OpenAlex | A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors

A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors

Work

Year: 2013

Type: article

Source: Cancer Chemotherapy and Pharmacology

Authors Shahneen Sandhu, K. Papadopoulos, Peter C.C. Fong, Amita Patnaik, Christina Messiou +9 more

Institutions Institute of Cancer Research, South Texas Accelerated Research Therapeutics, Janssen (Belgium), Janssen (Netherlands), Queen Mary University of London

Cites: 35

Cited by: 244

Related to: 10

FWCI: 7.304

Citation percentile (by year/subfield): 99.98

Topic: Chronic Lymphocytic Leukemia Research

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

Sustainable Development Goal Good health and well-being

Open Access status: closed